ALX ONCOLOGY HOLDINGS INC Debt Securities, Available-for-sale
ALX ONCOLOGY HOLDINGS INC (ALXO) had Debt Securities, Available-for-sale of $142.17 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets
us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2026-08-06
- 2026-06-30: Debt Securities, Available-for-sale $142.17M.
- 2026-03-31: Debt Securities, Available-for-sale $167.09M.
- 2025-12-31: Debt Securities, Available-for-sale $46.59M.
- 2025-09-30: Debt Securities, Available-for-sale $64.99M.
| Period end | Debt Securities, Available-for-sale |
|---|---|
| 2026-06-30 | $142.17M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $167.09M 10-Q · filed 2026-05-08 |
| 2025-12-31 | $46.59M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $64.99M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $81.83M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $105.32M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $129.18M 10-K · filed 2026-03-09 |
| 2024-09-30 | $161.52M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $184.65M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $182.09M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $215.82M 10-K · filed 2025-03-06 |
| 2023-09-30 | $195.96M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $223.49M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $252.27M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $274.26M 10-K · filed 2024-03-07 |
| 2022-09-30 | $283.34M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $313.05M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $332.21M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $357.18M 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |